scholarly journals Metastatic prostate cancer presenting as tumour-induced osteomalacia

2019 ◽  
Vol 12 (7) ◽  
pp. e229434
Author(s):  
Awo Akosua K Layman ◽  
Shivam Joshi ◽  
Sanjeev Shah
Keyword(s):  
Prostate Cancer ◽  
Lower Extremity ◽  
Parotid Gland ◽  
Basal Cell ◽  
Paraneoplastic Syndrome ◽  
Bone Pain ◽  
Metastatic Prostate Cancer ◽  
Prostate Adenocarcinoma ◽  
Malignant Tumours ◽  
Oncogenic Osteomalacia

Tumour-induced osteomalacia (TIO), or oncogenic osteomalacia, is a paraneoplastic syndrome marked by hypophosphataemia, renal phosphate wasting, bone pain, weakness, and fractures. The syndrome has been reported with both benign and malignant tumours including parotid gland basal cell tumours, thyroid carcinomas, colon adenocarcinomas, and prostate cancer. Often, the syndrome is marked by an insidious course during which patients present with generalised bony pain and weakness, which do not resolve until the underlying tumour is identified and treated. We present a case of a patient with Parkinson’s disease whose subacute weakness, lower extremity paresis, and renal phosphate wasting led to the synchronous diagnosis of metastatic prostate adenocarcinoma and TIO.

scholarly journals Characterization of a rat model of metastatic prostate cancer bone pain

2010 ◽  
pp. 213 ◽  
Author(s):  
Gurmit Singh ◽  
De Ciantis ◽  
Henry ◽  
Yashpal
Keyword(s):  
Prostate Cancer ◽  
Rat Model ◽  
Bone Pain ◽  
Metastatic Prostate Cancer

Metastatic Prostate Cancer Presenting as Lower Extremity Soft Tissue Mass: A Rare Case Presentation

Urology ◽  
2017 ◽  
Vol 99 ◽  
pp. e27-e28
Author(s):  
Paulette Cutruzzula ◽  
Daniel C. Edwards ◽  
David Cahn ◽  
Carmen Tong ◽  
Dana Kivlin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Soft Tissue ◽  
Lower Extremity ◽  
Rare Case ◽  
Metastatic Prostate Cancer ◽  
Soft Tissue Mass ◽  
Tissue Mass ◽  
Case Presentation

scholarly journals A novel immunocompetent model of metastatic prostate cancer‐induced bone pain

The Prostate ◽  
2020 ◽  
Vol 80 (10) ◽  
pp. 782-794
Author(s):  
Zhiqiang Liu ◽  
Stephen F. Murphy ◽  
Jian Huang ◽  
Lan Zhao ◽  
Christel C. Hall ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Pain ◽  
Metastatic Prostate Cancer

scholarly journals Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
Osama Diab ◽  
Dan Mcentire ◽  
Thamer Kassim ◽  
Ali Nayfeh ◽  
Abdel Rahman Dajani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Metastatic Prostate Cancer ◽  
Single Phase ◽  
Chemotherapeutic Agent ◽  
Case Reports ◽  
Prostate Adenocarcinoma ◽  
Stevens Johnson Syndrome ◽  
Treatment Regimens ◽  
Johnson Syndrome

Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to be aware of this relationship.

scholarly journals Generalized Lymphadenopathy: Unusual Presentation of Prostate Adenocarcinoma

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Bulent Cetin ◽  
Zeynep Cetin ◽  
Suleyman Buyukberber ◽  
Ipek Isık Gonul ◽  
Ilgin Sahiner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Prostate Biopsy ◽  
Immunohistochemical Staining ◽  
Metastatic Prostate Cancer ◽  
Inguinal Lymph Node ◽  
Prostate Adenocarcinoma ◽  
Rare Manifestation ◽  
Inguinal Lymphadenopathy ◽  
Generalized Lymphadenopathy

Generalized lymphadenopathy is a rare manifestation of metastatic prostate cancer. Here, we report the case of a 59-year-old male patient with supraclavicular, mediastinal, hilar, and retroperitoneal and inguinal lymphadenopathy, which suggested the diagnosis of lymphoma. There were no urinary symptoms. A biopsy of the inguinal lymph node was compatible with adenocarcinoma, whose prostatic origin was shown by immunohistochemical staining with PSA. The origin of the primary tumor was confirmed by directed prostate biopsy. We emphasize that a suspicion of prostate cancer in men with adenocarcinoma of undetermined origin is important for an adequate diagnostic and therapeutic approach.

Bisphosphonates Treatment in Metastatic Prostate Cancer

2005 ◽  
Vol 3 (2) ◽  
pp. 49-54
Author(s):  
F. Berardinelli ◽  
M. Iannucci ◽  
V. Verratti ◽  
W. Fusco ◽  
M. Nicolai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Pain ◽  
Metastatic Prostate Cancer ◽  
Common Site ◽  
The Third ◽  
Clinical Complications ◽  
Therapeutic Choice ◽  
Skeletal Related Events ◽  
Skeletal Integrity ◽  
Tumor Drugs

The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignancies that can cause destruction of skeletal bones include multiple myeloma and metastatic diseases of the lung, prostate and other solid cancers. The clinical complications include pain, fractures, compression of the spinal cord and hypercalcemia of malignancy. Bisphosphonates are bone-seeking agents originally designed to treat loss of bone density. Accumulating data show that they are effective in diseases in which there is upregulation of osteoclastic or osteolytic activity. Bisphosphonates can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. However, it is clear that bisphosphonates do not represent a decisive treatment in the care of metastases but a therapeutic choice in synergy with regular anti-tumor drugs. The preclinical and clinical data to support this are reviewed here.

Sign in / Sign up

Export Citation Format

Share Document